Goldman Sachs’s Iovance Biotherapeutics IOVA Stock Holding History

Goldman Sachs’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,000	Closed	-$416K	–	6574
2022 Q1	$416K	Buy	25,000 +2,800	+13%	+$43.3K	﹤0.01%	5452
2021 Q4	$424K	Buy	+22,200	New	+$489K	﹤0.01%	5478
2021 Q3	–	Sell	-40,000	Closed	-$1.04M	–	6355
2021 Q2	$1.04M	Buy	+40,000	New	+$1.04M	﹤0.01%	4727
2020 Q2	–	Sell	-60,000	Closed	-$1.8M	–	5343
2020 Q1	$1.8M	Buy	+60,000	New	+$1.59M	﹤0.01%	3377
2018 Q1	–	Sell	-2,600	Closed	-$21K	–	6134
2017 Q4	$21K	Sell	2,600 -2,500	-49%	-$20.1K	﹤0.01%	6108
2017 Q3	$40K	Buy	+5,100	New	+$32.3K	﹤0.01%	6304
2017 Q2	–	Sell	-1,900	Closed	-$14K	–	6851
2017 Q1	$14K	Sell	1,900 -600	-24%	-$4.4K	﹤0.01%	6572
2016 Q4	$17K	Buy	2,500 +1,100	+79%	+$7.57K	﹤0.01%	6677
2016 Q3	$12K	Sell	1,400 -101,100	-99%	-$855K	﹤0.01%	6850
2016 Q2	$830K	Buy	102,500 +100,600	+5,295%	+$632K	﹤0.01%	4363
2016 Q1	$10K	Buy	+1,900	New	+$10.4K	﹤0.01%	6895

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs's IOVA Position: Q2 2026 in Review

Goldman Sachs reduced its Iovance Biotherapeutics (IOVA) stake by 42% in Q2 2026, selling an estimated $13.9M and leaving 5,096,334 shares worth $21.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Goldman Sachs first reported a position in IOVA in Q1 2015 and has held it in 45 quarters since. The position peaked at $60.7M in Q1 2021. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Goldman Sachs held 5,096,334 shares of Iovance Biotherapeutics worth $21.2M as of Q2 2026.
Goldman Sachs sold 3,663,726 Iovance Biotherapeutics shares in Q2 2026, an estimated $13.9M.
Iovance Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2571 holding.
Goldman Sachs first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 45 quarters since.
Goldman Sachs's Iovance Biotherapeutics position peaked at $60.7M in Q1 2021.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.